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Apratoxin chaperones EGFR to its destruction
A 
small toxin from a cyanobacterium pushes growth-
promoting proteins such as the EGF receptor (EGFR) 
along an unusual path to destruction, report Shen et al.
Several oncogenic proteins, including EGFR, p53, and cyclin-
dependent kinases are collectively known as Hsp90 client proteins 
due to their reliance on the Hsp90 chaperone for maintaining their 
conformation and stability. Hsp90 inhibitors are undergoing cancer 
therapy trials, since disrupting the chaperone’s function results in its 
clients targeting to the proteasome for degradation.
The cyanobacterium compound Apratoxin A can also kill 
cancer cells—at least in vitro—but its mode of action was unknown. 
Shen et al. found that treating cells with Apratoxin A reduced 
the levels of several Hsp90 client proteins and prevented their 
interaction with Hsp90. But the toxin works in a different way to 
Hsp90 inhibitors like geldanamycin. Apratoxin A directly bound 
to chaperones of the Hsp70/Hsc70 family, stabilizing their 
association with Hsp90 client proteins such as EGFR. The client 
proteins could no longer bind Hsp90 and were instead delivered 
by Hsc70 to the lysosomes for degradation—a process called 
chaperone-mediated autophagy (CMA).
Blocking the CMA pathway prevented EGFR’s degradation in 
response to Apratoxin A. EGFR is the fi  rst membrane protein known 
to undergo CMA—a process previously thought to be reserved for 
cytosolic proteins. But Shen et al. identifi  ed a short sequence within 
EGFR that allows Hsc70 to recognize it as a CMA substrate. Apratoxin 
A’s ability to bind Hsp70/Hsc70 chaperones and induce the degradation 
of EGFR and other Hsp90 client proteins makes it an interesting 
candidate for cancer treatments, although author Shensi Shen warns 
that the drug is extremely toxic and will need to be further modifi  ed.
Shen, S., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200810183.
BDNF sends mixed signals
T
wo different forms 
of the same protein 
have a “yin and 
yang” function to either 
promote or inhibit synaptic 
activity.
The nervous system 
modifi   es the strength of 
its connections in response 
to changes in synaptic 
activity—a process known as synaptic plasticity. One source of 
this plasticity is the postsynaptic cell, which sends a retrograde 
signal back across the synapse to either strengthen or weaken 
further transmissions. One such retrograde signal is brain-
derived neurotrophic factor (BDNF), which promotes synaptic 
activity by binding to the TrkB receptor on presynaptic cells. 
But BDNF is also secreted in an uncleaved precursor form 
called pro-BDNF that binds to a different receptor called p75  NTR . 
Yang et al. wondered whether this form of the protein could have 
a different effect on synapses.
The team measured synaptic activity at neuromuscular junctions 
formed in vitro between Xenopus nerve and muscle cells. Adding a 
noncleavable version of pro-BDNF decreased activity at the synapses 
and caused nerve terminals to withdraw from the junctions. This 
behavior depended on p75  NTR , since knocking down the receptor in the 
presynaptic motor neurons prevented pro-BDNF’s inhibitory effects.
Postsynaptic muscle cells could also secrete endogenous pro-
BDNF to depress synaptic activity, the authors found, particularly if 
matrix metalloprotease (MMP) inhibitors were added to prevent the 
precursor from being processed to the mature form. This suggests 
that cleavage of pro-BDNF by MMPs is the key to switching the 
retrograde signal from depressing to potentiating synapses. Senior 
author Bai Lu now wants to study how the MMPs are regulated. He 
thinks that active presynaptic nerve cells secrete the enzymes into the 
synapse to cleave BDNF and strengthen the synaptic connection.
Yang, F., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200811147.
Pro-BDNF causes presynaptic 
nerve cells (green) to retract from 
postsynaptic muscle cells (red).
Decorin has Met a new receptor
A 
small extracellu-
lar matrix protein 
called decorin 
blocks multiple growth 
factor receptors in order to 
inhibit tumor formation, 
suggest Goldoni et al.
Mice lacking decorin 
are more susceptible to cancers, whereas increased levels of the protein 
can inhibit tumor growth and metastasis. Decorin was originally found 
to bind collagen fi  bers and regulate their assembly, but it can also 
inhibit EGF signaling by binding to and down-regulating the EGF 
receptor. Goldoni et al. wondered whether decorin might be even more 
promiscuous, and bind to other receptor tyrosine kinases as well.
The researchers screened 42 different receptors, and found 
that decorin also targeted Met—the receptor for the growth 
factor HGF, which promotes proliferation and invasion when 
constitutively activated in cancer cells. Although binding to decorin 
briefl  y activated Met, this only led to the receptor’s rapid down-
regulation via two different pathways—by degradation inside the 
cell and by the cleavage and release of its extracellular domain. 
According to senior author Renato Iozzo, decorin is therefore the 
fi  rst known antagonist of Met signaling.
Treating cells with decorin also caused the destruction 
of a downstream effector of Met called -catenin, stimulated 
apoptosis, and reduced cell motility. This latter effect relied 
on decorin’s ability to inhibit the EGF receptor as well as 
Met. Iozzo thinks that decorin could be a new way to treat 
cancers, which often have increased levels of multiple growth 
factor receptors and can survive therapies that only target a 
single pathway.
Goldoni, S., et al. 2009. J. Cell Biol. doi:10.1083/jcb.200901129.
Decorin binds to the Met receptor (green) 
and causes its internalization (arrows).